guest ::
| Home > Articles > Published articles > Antibacterial activity of T22, a specific peptidic ligand of the tumoral marker CXCR4 |
| Home > Articles > Published articles > Antibacterial activity of T22, a specific peptidic ligand of the tumoral marker CXCR4 |
(Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") (Institut d'Investigació Biomèdica Sant Pau) (Institut d'Investigació Biomèdica Sant Pau) (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
| Date: | 2021 |
| Abstract: | CXCR4 is a cytokine receptor used by HIV during cell attachment and infection. Overexpressed in the cancer stem cells of more than 20 human neoplasias, CXCR4 is a convenient antitumoral drug target. T22 is a polyphemusin-derived peptide and an effective CXCR4 ligand. Its highly selective CXCR4 binding can be exploited as an agent for the cell-targeted delivery and internalization of associated antitumor drugs. Sharing chemical and structural traits with antimicrobial peptides (AMPs), the capability of T22 as an antibacterial agent remains unexplored. Here, we have detected T22-associated antimicrobial activity and biofilm formation inhibition over Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa, in a spectrum broader than the reference AMP GWH1. In contrast to GWH1, T22 shows neither cytotoxicity over mammalian cells nor hemolytic activity and is active when displayed on protein-only nanoparticles through genetic fusion. Under the pushing need for novel antimicrobial agents, the discovery of T22 as an AMP is particularly appealing, not only as its mere addition to the expanding catalogue of antibacterial drugs. The recognized clinical uses of T22 might allow its combined and multivalent application in complex clinical conditions, such as colorectal cancer, that might benefit from the synchronous destruction of cancer stem cells and local bacterial biofilms. |
| Grants: | Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-229 Agencia Estatal de Investigación PID2019-105416RB-I00 Instituto de Salud Carlos III PI18/00650 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-865 Agencia Estatal de Investigación PID2019-107298RB-C22 Instituto de Salud Carlos III CP19/00028 Instituto de Salud Carlos III PI20/00400 Agencia Estatal de Investigación PID2019-111364RB-I00 |
| Note: | Altres ajuts: La Fundacio Marató de TV3 2019 (201941-31) and CIBER-BBN (project NANOPROTHER) |
| Note: | Altres ajuts: ICREA Academia award |
| Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Language: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Subject: | Antimicrobial peptides ; Nanoparticles ; Fusion proteins ; Inhibition of biofilm formation ; Multivalent drugs |
| Published in: | Pharmaceutics, Vol. 13, Issue 11 (November 2021) , art. 1922, ISSN 1999-4923 |
